Trial Profile
Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bimiralisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors PIQUR Therapeutics
- 30 Oct 2019 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2018 Status changed to active, no longer recruiting.